%0 Journal Article
%T Assessment of Extrapyramidal Symptoms and Hyperprolactinemia with Risperidone in Schizophrenic patients and Evaluation of their Management
%A Asha K Patel
%A Dharmesh Patel
%A Jayant B Dave
%J -
%D 2015
%R 10.18314/gjbs.v1i1.23
%X To check the occurrence of Extrapyramidal Symptoms (EPS) and Hyperprolactinemia (HP) in Schizophrenic£¿£¿£¿ patients receiving Risperidone drug and to check the efficacy of the drugs used for the management of these side£¿£¿£¿ effects. The study assumes significance in light of reported data that anticholinergic drugs are not very effective£¿£¿£¿ in relieving side effects and that they may impair efficacy of antipsychotic drugs to relieve positive symptoms. 30£¿£¿£¿ Schizophrenic patients receiving Risperidone drug were assessed for EPS & HP using Simpson Angus Rating£¿£¿£¿ Scale (SAS), Barnes Akathisia Rating Scale (BARS), Abnormal Involuntary Movement Scale (AIMS) & estimating£¿£¿£¿ prolactin level in blood. The EPS and HP side effects were treated with Trihexiphenidyl, propranolol or diazepam and cabergoline respectively and efficacy was studied for resolving the symptoms. The study revealed that£¿£¿£¿ 54.83% of patients on Risperidone showed EPS; majority of these patients (48.38%) developed Parkinsonism£¿£¿£¿ and rest (6.45%) developed Akathisia. Besides, 6.45% of the patients developed HP manifested as amenorrhea£¿£¿£¿ and menstrual irregularities. Trihexiphenidyl brought about resolution of most (88%) patients with Parkinsonism£¿£¿£¿ and partial resolution in remaining patients where tremors & rigidity persisted. propranolol and diazepam brought about the resolution of Akathisia. Cabergoline brought about satisfactory resolution of HP & associated symptoms£¿£¿£¿ in all the cases. About 65% of the patients receiving risperidone drug exhibited perceptible side effects. EPS, particularly£¿£¿£¿ Parkinsonism was found to be the major adverse effect. All the side effects were adequately resolved by£¿£¿£¿ the conventional drugs even at lower levels of the recommended dose improving the compliance of the treatment
%U https://www.gratisoa.org/journals/index.php/GJBS/article/view/23